Centanafadine is not FDA approved. It remains an investigational drug, meaning it has not yet been cleared for prescription or sale in the United States. However, it has reached a late stage in the approval process: the FDA accepted Otsuka Pharmaceutical’s New Drug Application (NDA) for centanafadine and granted it priority review, with a target decision date of July 24, 2026.
Where It Stands in the Approval Process
A drug goes through several regulatory stages before reaching pharmacies. First, the manufacturer submits a New Drug Application containing clinical trial data. The FDA then decides whether to accept or refuse that application for review. If accepted, the agency sets a target action date under the Prescription Drug User Fee Act (PDUFA), which is the deadline by which it aims to make a decision.
Centanafadine cleared that acceptance hurdle. The FDA also designated it for priority review, a status reserved for drugs that may offer meaningful advantages over existing treatments. Priority review shortens the FDA’s standard review timeline from about 12 months to roughly 8 months. The PDUFA date of July 24, 2026 is the earliest the FDA is expected to announce whether centanafadine is approved, requires changes, or is denied.
Priority review does not guarantee approval. It simply means the FDA considers the application important enough to evaluate on a faster timeline.
What Centanafadine Is Designed to Treat
Centanafadine is being developed for attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. If approved, it would join a crowded field of ADHD medications, but with a mechanism that sets it apart from most options currently available.
The drug works by blocking the recycling of three brain chemicals involved in attention and focus: norepinephrine, dopamine, and serotonin. Most existing ADHD medications target only one or two of these. Centanafadine has the strongest effect on norepinephrine, moderate activity on dopamine, and a weaker effect on serotonin. This triple-action profile is the basis for its development, though whether that translates into a meaningful clinical advantage is something the trial data helps clarify.
How It Compares to Existing ADHD Medications
An indirect comparison study presented at a major health economics conference evaluated centanafadine against three well-known ADHD treatments in adults. The results paint a mixed picture.
Centanafadine performed similarly to methylphenidate (the active ingredient in Ritalin and Concerta) and atomoxetine (Strattera), with no statistically significant difference in symptom reduction between them. However, it was less effective than lisdexamfetamine (Vyvanse), showing a meaningful gap of about 6 points on a standard ADHD symptom scale.
This positions centanafadine roughly in the middle of the current treatment landscape. It does not appear to outperform existing first-line options on raw efficacy. Its potential value likely rests on other factors: its unique mechanism, its side effect profile, and whether it works for people who haven’t responded well to other medications. These are exactly the kinds of considerations the FDA weighs during review.
Why It Received Priority Review
The priority review designation may seem surprising given the number of ADHD drugs already on the market. But the FDA grants this status when a drug has the potential to offer a significant improvement in the treatment of a serious condition. That improvement doesn’t have to mean better efficacy scores. It can also mean a new mechanism of action, a better safety profile, or an option for patients who can’t tolerate or don’t respond to current treatments.
Centanafadine is not a stimulant, which matters because stimulant medications, while effective, carry risks of dependence and are classified as controlled substances. The existing non-stimulant options are limited. Adding another non-stimulant with a distinct mechanism could expand choices for the millions of people managing ADHD, particularly those who experience problematic side effects from stimulants or prefer to avoid them.
What Happens Next
Between now and July 2026, the FDA will review the full body of clinical evidence Otsuka submitted, including safety data, manufacturing quality, and trial results across age groups. The agency may approve the drug as submitted, request additional data or labeling changes, or issue a complete response letter (essentially a rejection with feedback).
Until a decision is made, centanafadine cannot be prescribed or purchased. It is only available to participants in clinical trials. If approved, it would likely be marketed under a brand name and would need to go through insurance formulary decisions before becoming widely accessible.